Cited by 405Cannabis and Cannabinoid ResearchNeurotransmitter Receptor Influence on BehaviorNicotinic Acetylcholine Receptors Study

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats

Cohen, C., Perrault, G., Voltz, C., Steinberg, R., Soubrié, P.·2002·Behavioural Pharmacology

DOI 10.1097/00008877-200209000-00018

Open this paper in CoChat — free account

Abstract

The central CB(1) cannabinoid receptor has recently been implicated in brain reward function. In the present study we evaluated first the effects of the selective CB(1) receptor antagonist, SR141716, on the motivational effects of nicotine in the rat. Administration of SR141716 (0.3 and 1 mg/kg) decreased nicotine self-administration (0.03 mg/kg/injection). SR141716 (0.3-3 mg/kg) neither substituted for nicotine nor antagonized the nicotine cue in a nicotine discrimination procedure, but dose-dependently (0.01-1 mg/kg) antagonized the substitution of nicotine for D-amphetamine, in rats trained to discriminate D-amphetamine. Secondly, using brain microdialysis, SR141716 (1-3 mg/kg) blocked nicotine-induced dopamine release in the shell of the nucleus accumbens (NAc) and the bed nucleus of the stria terminalis. To investigate whether SR141716 would block the dopamine-releasing effects of another drug of abuse, we extended the neurochemical study to the effect of ethanol, consumption of which in rodents is reduced by SR141716. Dopamine release induced by ethanol in the NAc was also reduced by SR141716 (3 mg/kg). These results suggest that activation of the endogenous cannabinoid system may participate in the motivational and dopamine-releasing effects of nicotine and ethanol. Thus, SR141716 may be effective in reduction of alcohol consumption, as previously suggested, and as an aid for smoking cessation.

Integrity signals

Registry

Crossref · 10.1097/00008877-200209000-00018

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?
Berridge, K. C., & Robinson, T. E. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00019-8 · Cited by 4,127
Unresponsiveness to Cannabinoids and Reduced Addictive Effects of Opiates in CB 1 Receptor Knockout Mice
Ledent, C. A., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Impérato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,628
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,389
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi, M. L., Barth, F., Héaulme, M., Shire, D. J., Calandra, B., Congy, C., Martinez, S., Maruani, J., Neliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,762
Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586
The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking
Ikemoto, S., & Panksepp, J. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00023-5 · Cited by 1,450
Cannabinoid and Heroin Activation of Mesolimbic Dopamine Transmission by a Common µ 1 Opioid Receptor Mechanism
Tanda, G., Pontieri, F. E., & Chiara, G. D. (1997) · Science · doi:10.1126/science.276.5321.2048 · Cited by 1,085
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073
The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine
Corrigall, W. A., Franklin, K. B. J., Coen, K. M., & Clarke, P. B. S. (1992) · Psychopharmacology · doi:10.1007/bf02245149 · Cited by 829

Show all 77 references

Research works printed but not linked: 3

Cohen, 1999b, NIDA Research Monograph US Department of Health Human Services, 180, 197
deFonseca, 1999, Acta Pharmacol Sin, 20, 1109
De Vries, 2001, Nature, 7, 1511

Sorted by citations

Items 101–200 of 405

Uso terapêutico dos canabinoides em psiquiatria
Crippa, J. A. S., Zuardi, A. W., & Hallak, J. E. C. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000500009 · Cited by 93
The cannabinoid CB2 receptor is necessary for nicotine-conditioned place preference, but not other behavioral effects of nicotine in mice
Ignatowska-Jankowska, B. M., Muldoon, P. P., Lichtman, A. H., & Damaj, M. I. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3117-6 · Cited by 88
Role of cannabinoid CB2receptor in the reinforcing actions of ethanol
Ortega-Álvaro, A., Ternianov, A., Aracil-Fernández, A., Navarrete, F., García‐Gutiérrez, M. S., & Manzanares, J. (2013) · Addiction Biology · doi:10.1111/adb.12076 · Cited by 83
Involvement of cannabinoid CB1 receptors in drug addiction: effects of rimonabant on behavioral responses induced by cocaine.
Filip, M., Gołda, A., Zaniewska, M., McCreary, A. C., Nowak, E., Kolasiewicz, W., & Przegaliński, E. (2006) · PubMed · Cited by 83
Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitization
Lesscher, H. M. B., Hoogveld, E., Burbach, J. P. H., van Ree, J. M., & Gerrits, M. A. F. M. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.04.003 · Cited by 79
Hub and switches: endocannabinoid signalling in midbrain dopamine neurons
Melis, M., & Pistis, M. (2012) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2011.0383 · Cited by 81
Chronic ethanol exposure increases voluntary home cage intake in adult male, but not female, Long–Evans rats
Morales, M., McGinnis, M. M., & McCool, B. A. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.10.016 · Cited by 78
Potential substrates for nicotine and alcohol interactions: A focus on the mesocorticolimbic dopamine system
Doyon, W. M., Thomas, A. M., Ostroumov, A., Dong, Y., & Dani, J. A. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.07.007 · Cited by 78
Phasic D1 and tonic D2 dopamine receptor signaling double dissociate the motivational effects of acute nicotine and chronic nicotine withdrawal
Grieder, T. E., George, O., Tan, H., George, S. R., Foll, B. L., Laviolette, S. R., & van der Kooy, D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114422109 · Cited by 84
Recognising Nicotine: The Neurobiological Basis of Nicotine Discrimination
Smith, J. W., & Stolerman, I. P. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-69248-5_11 · Cited by 75
Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks
Gadde, K. M., & Allison, D. B. (2006) · Circulation · doi:10.1161/circulationaha.105.596130 · Cited by 76
Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion
Cryan, J. F., Gasparini, F., Heeke, G. V., & Markou, A. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02890-3 · Cited by 77
The CB1Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability
Gueye, A. B., Pryslawsky, Y., Trigo, J. M., Poulia, N., Delis, F., Antoniou, K., Loureiro, M., Laviolette, S. R., Vemuri, K., Makriyannis, A., et al. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw068 · Cited by 74
Varenicline in the treatment of tobacco dependence
Fagerström, K. O. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s927 · Cited by 78
Rimonabant: Just an Antiobesity Drug? Current Evidence on Its Pleiotropic Effects
Bifulco, M., Grimaldi, C., Gazzerro, P., Pisanti, S., & Santoro, A. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.033118 · Cited by 74
Developments in pharmacotherapy for tobacco dependence: past, present and future
Foulds, J., Steinberg, M. B., Williams, J. M., & Ziedonis, D. M. (2006) · Drug and Alcohol Review · doi:10.1080/09595230500459529 · Cited by 75
Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys.
Schindler, C. W., Redhi, G. H., Vemuri, K., Makriyannis, A., Le Foll, B., Bergman, J., Goldberg, S. R., & Justinova, Z. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.27 · Cited by 73
Design, Synthesis, and Biological Evaluation of New 1,8-Naphthyridin-4(1H)-on-3-carboxamide and Quinolin-4(1H)-on-3-carboxamide Derivatives as CB2Selective Agonists
Manera, C., Benetti, V., Castelli, M. P., Cavallini, T., Lazzarotti, S., Pibiri, F., Saccomanni, G., Tuccinardi, T., Vannacci, A., Martinelli, A., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0603466 · Cited by 72
Non-Nicotinic Therapies for Smoking Cessation
Siu, E. C. K., & Tyndale, R. F. (2007) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105354 · Cited by 69
The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine‐induced dopamine elevations in the nucleus accumbens shell in rats
Scherma, M., Justinová, Z., Zanettini, C., Panlilio, L. V., Mascia, P., Fadda, P., Fratta, W., Makriyannis, A., Vadivel, S. K., Gamaleddin, I., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01467.x · Cited by 74
The CB1 antagonist rimonabant (SR141716) blocks cue-induced reinstatement of cocaine seeking and other context and extinction phenomena predictive of relapse
Ward, S. J., Rosenberg, M., Dykstra, L., & Walker, E. A. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.07.002 · Cited by 68
Presynaptic G Protein-Coupled Receptors: Gatekeepers of Addiction?
Johnson, K. A., & Lovinger, D. M. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00264 · Cited by 67
Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving
Heidbreder, C. A., & Hagan, J. J. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.08.013 · Cited by 68
The role of the cannabinoid system in nicotine addiction
Castañé, A., Berrendero, F., & Maldonado, R. J. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.025 · Cited by 67
Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so far
Flores, Á., Maldonado, R. J., & Berrendero, F. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00256 · Cited by 74
Animal Models of Nicotine Exposure: Relevance to Second-Hand Smoking, Electronic Cigarette Use, and Compulsive Smoking
Cohen, A., & George, O. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00041 · Cited by 70
Relationship of Type 1 Cannabinoid Receptor Availability in the Human Brain to Novelty-Seeking Temperament
Laere, K. V., Goffin, K. E., Bormans, G. M., Casteels, C., Mortelmans, L., Hoon, J. N. J. M. D., Grachev, I. D., Vandenbulcke, M., & Pieters, G. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.530 · Cited by 67
ROLE OF THE ENDOCANNABINOID SYSTEM IN THE DEVELOPMENT OF TOLERANCE TO ALCOHOL
Basavarajappa, B. S., & Hungund, B. L. (2004) · Alcohol and Alcoholism · doi:10.1093/alcalc/agh111 · Cited by 67
Effects of a Selective Cannabinoid CB2 Agonist and Antagonist on Intravenous Nicotine Self Administration and Reinstatement of Nicotine Seeking
Gamaleddin, I., Zvonok, A. M., Makriyannis, A., Goldberg, S. R., & Foll, B. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029900 · Cited by 66
The anandamide transport inhibitor AM404 reduces ethanol self‐administration
Cippitelli, A., Bilbao, A., Gorriti, M. Á., Navarro, M. A., Massi, M., Piomelli, D., Ciccocioppo, R., & de Fonseca, F. R. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05665.x · Cited by 66
Cannabis and alcohol – a close friendship
Mechoulam, R., & Parker, L. A. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00107-x · Cited by 66
Pharmacotherapy of Dual Substance Abuse and Dependence
Kenna, G. A., Nielsen, D. M., Mello, P., Schiesl, A., & Swift, R. M. (2007) · CNS Drugs · doi:10.2165/00023210-200721030-00003 · Cited by 65
Suppression by the cannabinoid CB1 receptor antagonist, rimonabant, of the reinforcing and motivational properties of a chocolate-flavoured beverage in rats
Maccioni, P., Pes, D., Carai, M. A. M., Gessa, G. L., & Colombo, G. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282fe8888 · Cited by 65
Effects of the cannabinoid CB1 receptor allosteric modulator ORG 27569 on reinstatement of cocaine- and methamphetamine-seeking behavior in rats
Li, J., Qiu, Y., Zhang, Y., & Li, J. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.08.004 · Cited by 65
The genetic basis of the endocannabinoid system and drug addiction in humans
López‐Moreno, J. A., Echeverry‐Alzate, V., & Bühler, K. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111416689 · Cited by 64
Ecological momentary assessment of working memory under conditions of simultaneous marijuana and tobacco use
Schuster, R. M., Mermelstein, R. J., & Hedeker, D. (2016) · Addiction · doi:10.1111/add.13342 · Cited by 69
Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors
Bátkai, S., Pacher, P., Járai, Z., Wagner, J. A., & Kunos, G. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00184.2004 · Cited by 64
Analysis of the Endocannabinoid System by Using CB1 Cannabinoid Receptor Knockout Mice
Valverde, O., Karsak, M., & Zimmer, A. (2005) · Springer eBooks · doi:10.1007/3-540-26573-2_4 · Cited by 61
Substituted 5,5‘-Diphenyl-2-thioxoimidazolidin-4-one as CB1 Cannabinoid Receptor Ligands: Synthesis and Pharmacological Evaluation
Muccioli, G. G., Martin, D. V., Scriba, G. K. E., Poppitz, W., Poupaert, J. H., Wouters, J., & Lambert, D. M. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049263k · Cited by 62
The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats
Need, A. B., Davis, R. J., Alexander-Chacko, J. T., Eastwood, B. J., Chernet, E., Phebus, L. A., Sindelar, D. K., & Nomikos, G. G. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0234-x · Cited by 61
Design, Synthesis, Biological Properties, and Molecular Modeling Investigations of Novel Tacrine Derivatives with a Combination of Acetylcholinesterase Inhibition and Cannabinoid CB1Receptor Antagonism
Lange, J. H. M., Coolen, H. K. A. C., van der Neut, M. A. W., Borst, A. J. M., Stork, B., Verveer, P. C., & Kruse, C. G. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901614b · Cited by 61
THC reduces the anticipatory nucleus accumbens response to reward in subjects with a nicotine addiction
Jansma, J. M., van Hell, H. H., Vanderschuren, L. J. M. J., Bossong, M. G., Jager, G., Kahn, R. S., & Ramsey, N. F. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.6 · Cited by 58
Role of the endogenous cannabinoid system in nicotine addiction: novel insights
Gamaleddin, I. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00041 · Cited by 59
The Endocannabinoid Signaling System: A Potential Target for Next- Generation Therapeutics for Alcoholism
Basavarajappa, B. S. (2007) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955707781387920 · Cited by 57
Novel Pharmacological Approaches for Treating Tobacco Dependence and Withdrawal
Buchhalter, A. R., Fant, R. V., & Henningfield, J. E. (2008) · Drugs · doi:10.2165/00003495-200868080-00005 · Cited by 57
Suppressing effect of the cannabinoid CB1 receptor antagonist, SR 141716, on alcohol's motivational properties in alcohol-preferring rats
Colombo, G., Vacca, G., Serra, S., Carai, M. A. M., & Gessa, G. L. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.07.069 · Cited by 57
Convergent pharmacological mechanisms in impulsivity and addiction: insights from rodent models
Jupp, B., & Dalley, J. W. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12787 · Cited by 58
Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives
Scherma, M., Muntoni, A. L., Melis, M., Fattore, L., Fadda, P., Fratta, W., & Pistis, M. (2016) · Psychopharmacology · doi:10.1007/s00213-015-4196-3 · Cited by 59
Combined low dose treatment with opioid and cannabinoid receptor antagonists synergistically reduces the motivation to consume alcohol in rats
Gallate, J. E., Mallet, P. E., & McGregor, I. S. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1694-5 · Cited by 55
The Cannabinoid CB1 Receptor Antagonist, Rimonabant, as a Promising Pharmacotherapy for Alcohol Dependence: Preclinical Evidence
Colombo, G., Orrù, A., Lai, P., Cabras, C., Maccioni, P., Rubio, M., Gessa, G. L., & Carai, M. A. M. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0017-y · Cited by 55
SLV330, a cannabinoid CB1 receptor antagonist, attenuates ethanol and nicotine seeking and improves inhibitory response control in rats
de Bruin, N. M. W. J., Lange, J. H. M., Kruse, C. G., Herremans, A. H. J., Schoffelmeer, A. N. M., Drimmelen, M. V., & Vries, T. J. D. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.013 · Cited by 50
Endocannabinoids Promote Cocaine-Induced Impulsivity and Its Rapid Dopaminergic Correlates
Hernández, G., Oleson, E. B., Gentry, R. N., Abbas, Z., Bernstein, D. L., Arvanitogiannis, A., & Cheer, J. F. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.09.005 · Cited by 51
The Volitional Nature of Nicotine Exposure Alters Anandamide and Oleoylethanolamide Levels in the Ventral Tegmental Area
Buczynski, M. W., Polis, I. Y., & Parsons, L. H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.210 · Cited by 49
Alcohol Interaction with Cocaine, Methamphetamine, Opioids, Nicotine, Cannabis, and γ-Hydroxybutyric Acid
Singh, A. K. (2019) · Biomedicines · doi:10.3390/biomedicines7010016 · Cited by 51
Nicotine and Non-nicotine Smoking Cessation Pharmacotherapies
Frishman, W. H., Mitta, W., Kupersmith, A., & Ky, T. (2006) · Cardiology in Review · doi:10.1097/01.crd.0000172309.06270.25 · Cited by 48
Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids
Sholler, D. J., Huestis, M. A., Amendolara, B., Vandrey, R. G., & Cooper, Z. D. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.173059 · Cited by 50
Endocannabinoid regulation of relapse mechanisms
Fattore, L., Fadda, P., & Fratta, W. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.09.004 · Cited by 49
Cannabidiol in the context of substance use disorder treatment: A systematic review
Paulus, V., Billieux, J., Benyamina, A., & Karila, L. (2022) · Addictive Behaviors · doi:10.1016/j.addbeh.2022.107360 · Cited by 52
Effects of a Cannabinoid1 Receptor Antagonist and Serotonin2C Receptor Agonist Alone and in Combination on Motivation for Palatable Food: A Dose-Addition Analysis Study in Mice
Ward, S. J., Lefever, T. W., Jackson, C., Tallarida, R. J., & Walker, E. A. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.131771 · Cited by 47
Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies
Sloan, M. E., Grant, C. W., Gowin, J. L., Ramchandani, V. A., & Foll, B. L. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0081-z · Cited by 47
The Effects of Cholinergic and Dopaminergic Antagonists on Nicotine-Induced Cerebral Neurotransmitter Changes
Rossi, S., Singer, S., Shearman, E., Sershen, H. W., & Lajtha, Á. (2005) · Neurochemical Research · doi:10.1007/s11064-005-2689-x · Cited by 46
Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats
Zaniewska, M., McCreary, A. C., Przegaliński, E., & Filip, M. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.04.034 · Cited by 46
Modulation of morphine-induced Fos-immunoreactivity by the cannabinoid receptor antagonist SR 141716
Singh, M. E., Verty, A. N. A., Price, I., McGregor, I. S., & Mallet, P. E. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.08.008 · Cited by 45
Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders
Beardsley, P. M., & Thomas, B. F. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00003 · Cited by 44
Cortico-limbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling
Kodas, E., Cohen, C., Louis, C., & Griebel, G. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0813-0 · Cited by 45
Calcium-dependent mechanisms of the reinstatement of nicotine-conditioned place preference by drug priming in rats
Biała, G., & Budzyńska, B. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.12.005 · Cited by 45
Impulsive Behavior and Nicotinic Acetylcholine Receptors
Ohmura, Y., Tsutsui‐Kimura, I., & Yoshioka, M. (2012) · Journal of Pharmacological Sciences · doi:10.1254/jphs.11r06cr · Cited by 47
Pooled analysis of three randomized, double‐blind, placebo controlled trials with rimonabant for smoking cessation
Robinson, J. D., Cinciripini, P. M., Karam‐Hage, M., Aubin, H., Dale, L. C., NIAURA, R. S., Anthenelli, R. M., & the STRATUS Group (2017) · Addiction Biology · doi:10.1111/adb.12508 · Cited by 43
Contextual stimuli modulate extinction and reinstatement in rodents self-administering intravenous nicotine
Wing, V. C., & Shoaib, M. C. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1211-y · Cited by 44
Diacylglycerol lipase disinhibits VTA dopamine neurons during chronic nicotine exposure
Buczynski, M. W., Herman, M. A., Hsu, K., Natividad, L. A., Irimia, C., Polis, I. Y., Pugh, H. M., Chang, J. W., Niphakis, M. J., Cravatt, B. F., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522672113 · Cited by 42
Mechanism-based medication development for the treatment of nicotine dependence
Xi, Z., Spiller, K. J., & Gardner, E. L. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.46 · Cited by 42
SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats
Lallemand, F., & Witte, P. D. (2006) · Alcohol · doi:10.1016/j.alcohol.2006.08.001 · Cited by 42
Therapeutic advances in the treatment of nicotine addiction: present and future
Casella, G., Caponnetto, P., & Polosa, R. (2010) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622310374896 · Cited by 42
Endocannabinoids and striatal function
Moreira, F. A., Jupp, B., Belin, D., & Dalley, J. W. (2014) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000109 · Cited by 44
Role of cannabinoidergic mechanisms in ethanol self-administration and ethanol seeking in rat adult offspring following perinatal exposure to Δ9-tetrahydrocannabinol
Economidou, D., Mattioli, L., Ubaldi, M., Lourdusamy, A., Soverchia, L., Hardiman, G., Campolongo, P., Cuomo, V., & Ciccocioppo, R. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.05.008 · Cited by 41
The Endocannabinoid System: A New Molecular Target for the Treatment of Tobacco Addiction
Scherma, M., Fadda, P., Foll, B. L., Forget, B., Fratta, W., Goldberg, S. R., & Tanda, G. (2008) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152708786927859 · Cited by 43
Endocannabinoid signaling in neurotoxicity and neuroprotection
Pope, C., Mechoulam, R., & Parsons, L. H. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.12.002 · Cited by 40
Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9‐tetrahydrocannabinol‐induced central nervous system and heart rate effects in humans
Klumpers, L. E., Roy, C., Ferron‐Brady, G., Turpault, S., Poitiers, F., Pinquier, J., van Hasselt, J. G. C., Zuurman, L., Erwich, F. A. S., & van Gerven, J. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12071 · Cited by 40
Neuropharmacology of the Interoceptive Stimulus Properties of Nicotine
Wooters, T. E., Bevins, R. A., & Bardo, M. T. (2009) · Current Drug Abuse Reviews · doi:10.2174/1874473710902030243 · Cited by 42
Effects of baclofen on conditioned rewarding and discriminative stimulus effects of nicotine in rats
Foll, B. L., Wertheim, C. E., & Goldberg, S. R. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.07.074 · Cited by 41
Basolateral amygdala CB1 cannabinoid receptors mediate nicotine-induced place preference
Hashemizadeh, S., Sardari, M., & Rezayof, A. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.01.010 · Cited by 39
Dopamine D3receptor ligands for the treatment of tobacco dependence
Foll, B. L., Goldberg, S. R., & Sokoloff, P. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.1.45 · Cited by 39
Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse
Skike, C. E. V., Maggio, S. E., Reynolds, A. R., Casey, E. M., Bardo, M. T., Dwoskin, L. P., Prendergast, M., & Nixon, K. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.004 · Cited by 43
Drug Addiction
Justinová, Z., Panlilio, L. V., & Goldberg, S. R. (2009) · Current topics in behavioral neurosciences · doi:10.1007/978-3-540-88955-7_13 · Cited by 40
Blockade by the Cannabinoid CB1 Receptor Antagonist, Rimonabant (SR141716), of the Potentiation by Quinelorane of Food-Primed Reinstatement of Food-Seeking Behavior
Duarte, C., Alonso, R., Bichet, N., Cohen, C., Soubrié, P., & Thiébot, M.-H. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300370 · Cited by 39
Effects of Prenatal Nicotine, THC, or Co-Exposure on Cognitive Behaviors in Adolescent Male and Female Rats
Lallai, V., Manca, L., Sherafat, Y., & Fowler, C. D. (2022) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntac018 · Cited by 41
Medial forebrain bundle stimulation evokes endocannabinoid-mediated modulation of ventral tegmental area dopamine neuron firing in vivo
Pillolla, G., Melis, M., Perra, S., Muntoni, A. L., Gessa, G. L., & Pistis, M. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0733-z · Cited by 39
Effect of CB1 Receptor Blockade on Food-Reinforced Responding and Associated Nucleus Accumbens Neuronal Activity in Rats
Hernández, G., & Cheer, J. F. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1833-12.2012 · Cited by 39
Individual and combined effects of cannabis and tobacco on drug reward processing in non-dependent users
Hindocha, C., Lawn, W., Freeman, T. P., & Curran, H. V. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4698-2 · Cited by 36
The role of fatty acid amide hydrolase inhibition in nicotine reward and dependence
Muldoon, P. P., Lichtman, A. H., Parsons, L. H., & Damaj, M. I. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.05.015 · Cited by 39
Rats on the grog: Novel pharmacotherapies for alcohol craving
McGregor, I. S., & Gallate, J. E. (2004) · Addictive Behaviors · doi:10.1016/j.addbeh.2004.06.011 · Cited by 37
Endocannabinoids at the synapse and beyond: implications for neuropsychiatric disease pathophysiology and treatment
Scheyer, A. F., Yasmin, F., Naskar, S., & Patel, S. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01438-7 · Cited by 37
Cannabinoid receptor ligands suppress memory-related effects of nicotine in the elevated plus maze test in mice
Biała, G., & Kruk, M. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.04.004 · Cited by 37
Whole tobacco smoke extracts to model tobacco dependence in animals
Brennan, K. A., Laugesen, M., & Truman, P. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.07.014 · Cited by 39
Differential associations of combined vs. isolated cannabis and nicotine on brain resting state networks
Filbey, F. M., Gohel, S., Prashad, S., & Biswal, B. B. (2018) · Brain Structure and Function · doi:10.1007/s00429-018-1690-5 · Cited by 35
Rimonabant: A cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors
Tonstad, S. (2006) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2005.10.011 · Cited by 36
Treatment of Tobacco Use and Dependence: The Role of the Dental Professional
Walsh, M. M., & Ellison, J. A. (2005) · Journal of Dental Education · doi:10.1002/j.0022-0337.2005.69.5.tb03940.x · Cited by 36
Blocking the Cannabinoid Receptors: Drug Candidates and Therapeutic Promises
Muccioli, G. G. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790153 · Cited by 36
AM404 attenuates reinstatement of nicotine seeking induced by nicotine-associated cues and nicotine priming but does not affect nicotine- and food-taking
Gamaleddin, I., Guranda, M., Scherma, M., Fratta, W., Makriyannis, A., Vadivel, S. K., Goldberg, S. R., & Foll, B. L. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113477710 · Cited by 34
Endocannabinoids and the Processing of Value-Related Signals
Melis, M., Muntoni, A. L., & Pistis, M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00007 · Cited by 36

Authors: Cohen, C., Perrault, G., Voltz, C., Steinberg, R., & Soubrié, P.
Affiliations: Sanofi (France) (FR)
Corresponding author: Cohen, C.
Venue: Behavioural Pharmacology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2002-09
Volume: 13
Issue: 5
Pages: 451-463
ISSN: 0955-8810 (ISSN-L)
DOI: 10.1097/00008877-200209000-00018
OpenAlex: W2001109168
Cited by: 396
References: 77
Citations by year: 2026: 5 · 2025: 2 · 2024: 4 · 2023: 11 · 2022: 9 · 2021: 7 · 2020: 13 · 2019: 8 · 2018: 8 · 2017: 11 · 2016: 20 · 2015: 14 · 2014: 9 · 2013: 19 · 2012: 16
FWCI: 16.34
Type: journal article
Language: en
Open access: closed
Locations: Behavioural Pharmacology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
Keywords: SR141716, nicotine self-administration, dopamine release, nucleus accumbens shell, bed nucleus of the stria terminalis, endocannabinoid system, drug reward, alcohol consumption reduction, smoking cessation
MeSH terms: Rimonabant, Ethanol, Animals, Brain Chemistry, Central Nervous System Depressants, Discrimination Learning, Dopamine, Extracellular Space, Male, Motivation, Nicotine, Nucleus Accumbens, Piperidines, Pyrazoles, Receptors, Drug, Reinforcement, Psychology, Self Administration, Rats, Sprague-Dawley, Rats, Wistar, Microdialysis, Nicotinic Agonists, Nicotinic Antagonists, Receptors, Cannabinoid, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks